IMPA1 and neoplasm: Moreover, since the combination of EVs with two of the candidate proteins, IdeS or ImpA, can not only enhance the drug delivery efficiency but also further improve tumor targeting specificity or promote tumor deactivation, the study here also enables an innovative synergistic EV-based cancer therapy approach.